Wyeth Pharmaceuticals recently submitted two New Drug Applications (NDA) to the USFDA:
1) bazedoxifene: a Selective Estrogen Receptor Modulator (SERM) investigated for the prevention of postmenopausal osteoporosis.
2) desvenlafaxine succinate: a non-hormonal agent studied for the treatment of moderate to severe vasomotor symptoms associated with menopause, such as hot flashes and night sweats.
"If approved, both bazedoxifene and desvenlafaxine succinate will give physicians additional options to help meet the individualized needs of their menopausal patients," says Joseph Camardo, MD, Senior Vice President, Global Medical Affairs, Wyeth Pharmaceuticals.
"The simultaneous submission of these two separate NDAs emphasizes Wyeth's position as a leader and innovator in women's health.
Meeting the health care needs of women worldwide is a goal that Wyeth continuously supports and seeks to provide.
Read the full press release.
Comment Preview